With the continuous progress of science and technology and the improvement of medical level, drug research and development has become one of the core competitiveness in the pharmaceutical industry. With the strategic deployment of "R&D generation, reserve generation, and transformation generation", as well as deep cultivation in the fields of cardiovascular and cerebrovascular diseases, tumors and infectious diseases, Yuekang Pharmaceutical is rapidly rising to become a cutting-edge force in the pharmaceutical field.
Yuekang Pharmaceutical focuses on the future, and currently has as many as 18 innovative drug projects under development, covering three major fields, including cardiovascular and cerebrovascular diseases, tumors and infectious diseases. By consolidating the four major technical routes of nucleic acid drugs, peptide drugs, small molecule drugs and characteristic traditional Chinese medicine preparations, the company has ushered in a series of important breakthroughs in the research and development of innovative drugs. This multi-pronged strategy includes not only independent research and development, but also cooperative development and introduction with external parties, which has enabled Yuekang to form a differentiated competitive advantage in the field of innovative drugs.
In the field of nucleic acid drugs, Yuekang Pharmaceutical has obtained the company's first important patent for nucleic acid drug delivery system, and this technological breakthrough plays a key role in the development of nucleic acid drugs. The company has fully invested in the research and development of nucleic acid platform delivery system technology, and has been authorized 10 patents for nucleic acid drug delivery system so far. Among them, the LNP delivery system is currently the only mRNA drug delivery system that has been verified by large-scale clinical trials, which has laid a solid foundation for the company's technical strength in the field of nucleic acids.
In addition, Yuekang Pharmaceutical has also completed the filing and registration of cationic lipid excipients with independent intellectual property rights (YK-009), becoming the first enterprise in China to complete the domestic and foreign filing of cationic lipids with independent intellectual property rights. The company has formed a systematic patent layout in the field of LNP delivery technology, and at the same time realized the large-scale production of excipients, provided support for the progress of nucleic acid drug pipelines, and provided important support for domestic and foreign nucleic acid drug companies, which is an important milestone.
Today, Yuekang Pharmaceutical has established a comprehensive drug development platform based on nucleic acid drugs, including target discovery platform, high-throughput screening platform, process development and large-scale preparation platform, analysis and quality control platform, etc. The system layout has been carried out on the underlying key technologies of nucleic acid drugs, and the R&D capabilities of the whole chain from target screening and confirmation, sequence design, antigen design, efficacy evaluation, CMC small and pilot test, clinical trials to registration and application have been strengthened. The comprehensive construction of the company provides solid support for the future research and development of innovative drugs.
With years of innovative practice and systematic technical layout, Yuekang Pharmaceutical has made remarkable achievements in the field of medicine. Through continuous innovation, Yuekang continues to make breakthroughs in the field of new drug research and development, which is expected to provide patients with more safe and effective solutions, promote the development of medical science and technology, and inject new vitality into the innovation of the global pharmaceutical industry.